Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/10770
Title: An audit of the use of granulocyte colony-stimulating factor in septic shock.
Authors: Stephens, D P
Fisher, D A
Currie, B J
Affiliation: Royal Darwin Hospital, Tiwi, Northern Territory, Australia. dianne.stephens@nt.gov.au.
Issue Date: Apr-2002
Citation: Internal medicine journal 2002-04; 32(4): 143-8
Abstract: Granulocyte colony-stimulating factor (G-CSF) stimulates the production of neutrophils and modulates the function and activity of developing and mature neutrophils. In septic shock, the immune system can be considered one of the failing organ systems. G-CSF improves immune function and may be a useful adjunctive therapy in patients with septic shock. To evaluate the introduction of G-CSF as an adjunct to our standard treatment for community-acquired septic shock. We performed a prospective data collection and analysis to determine whether the addition of G-CSF to our standard treatment for community-acquired septic shock was associated with improved hospital outcome, compared with an historical cohort of similar patients. We included all patients admitted to the Intensive Care Unit (ICU) with community-acquired septic shock between December 1998 and March 2000. Patients received 300 microg G-CSF intravenously daily for 10 days in addition to our standard treatment for community-acquired septic shock. G-CSF was discontinued early if the patient was discharged from ICU before 10 days or if the absolute neutrophil count exceeded 75 x 10(6)/mL. A total of 36 patients with community-acquired septic shock, an average Apache 2 score of 26.7, and a predicted mortality of 0.79, were treated with G-CSF from December 1998 to March 2000. Hospital mortality was 31% compared with an historical cohort of 11 similar patients with a hospital mortality of 73% (P = 0.018). In the subgroup of patients with melioidosis septic shock, the hospital survival improved from 5% to 100% (P < 0.0001). No significant adverse events occurred as a result of the administration of G-CSF. G-CSF is a safe adjunctive therapy in community-acquired septic shock and may be associated with improved outcome. The use of G-CSF in septic shock should undergo further investigation to define subgroups of patients who may benefit from G-CSF. The use of G-CSF in patients with septic shock due to Burkholderia pseudomallei is recommended.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/10770
ISSN: 1444-0903
Type: Comparative Study
Journal Article
Subjects: Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
Australia
Chemotherapy, Adjuvant
Cohort Studies
Community-Acquired Infections
Critical Care
Drug Therapy, Combination
Female
Granulocyte Colony-Stimulating Factor
Hospital Mortality
Humans
Intensive Care Units
Male
Middle Aged
Prospective Studies
Reference Values
Severity of Illness Index
Shock, Septic
Survival Rate
Treatment Outcome
Medical Audit
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.